Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517228 | 1.00 | POLB (0.35) | POLBHTTSMN1; SMN2HSD17B10HPGD | |
| SCHEMBL23549777 | 0.81 | SMN1; SMN2 (0.30) | SMN1; SMN2HSD17B10HPGDALDH1A1RAB9A | |
| SCHEMBL23549776 | 0.81 | SMN1; SMN2 (0.30) | SMN1; SMN2HSD17B10HPGDALDH1A1RAB9A | |
| SCHEMBL3207866 | 0.81 | POLB (0.35) | POLBHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL3207877 | 0.81 | POLB (0.35) | POLBHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL23549843 | 0.81 | SMN1; SMN2 (0.35) | POLBHTTSMN1; SMN2HSD17B10HPGD | |
| SCHEMBL23549842 | 0.81 | SMN1; SMN2 (0.35) | POLBHTTSMN1; SMN2HSD17B10HPGD | |
| SCHEMBL3195912 | 0.80 | LMNA (0.38) | POLBHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL3195926 | 0.80 | LMNA (0.38) | POLBHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL23549818 | 0.80 | POLB (0.34) | POLBHTTSMN1; SMN2HSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | POLB 1792/4885HTT 2987/4885SMN1; SMN2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.